HCAT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
56.3M
-20.2%
70.5M
-0.4%
70.8M
-5.3%
74.7M
-2.2%
76.3M
Cost of Revenue
32.2M
-9.5%
35.6M
+0.9%
35.3M
-0.0%
35.3M
-8.3%
38.5M
Gross Profit
24.0M
-31.0%
34.9M
-1.7%
35.5M
-10.0%
39.4M
+4.1%
37.8M
Operating Expenses
39.8M
-44.2%
71.3M
-49.7%
141.9M
+13.1%
125.5M
+126.8%
55.3M
R&D
9.5M
-13.8%
11.0M
+12.8%
9.8M
-1.3%
9.9M
-19.3%
12.3M
SG&A
20.6M
-7.7%
22.3M
-9.2%
24.5M
+15.7%
21.2M
-30.3%
30.4M
Operating Income
-15752000
+56.8%
-36480000
+65.7%
-106477000
-23.7%
-86080000
-391.6%
-17509000
EBITDA
-6024000
-489.7%
1.5M
+35.7%
1.1M
-86.2%
8.3M
+268.7%
-4895000
Net Income
40.5M
+199.9%
-40537000
+63.5%
-111026000
-22.0%
-91025000
-309.5%
-22229000
EPS (Basic)
$0.54
+198.2%
$-0.55
+64.1%
$-1.53
-19.5%
$-1.28
-300.0%
$-0.32
EPS (Diluted)
$0.53
+196.4%
$-0.55
+64.1%
$-1.53
-19.5%
$-1.28
-300.0%
$-0.32
Shares (Diluted)
75.9M
+2.7%
74.0M
+1.9%
72.6M
+2.2%
71.0M
+0.9%
70.4M
Health Catalyst (HCAT) — Financials